Ironwood Pharma (IRWD) Posts Q1 Loss of 38c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Aegis Maintains Ironwood Pharma (IRWD) at Buy; Still Positive on LINZESS Amid Slower Start
April 29, 2014 12:02 PM EDTAegis Capital reaffirms its Buy rating and $16 target price on Ironwood Pharmaceuticals (Nasdaq: IRWD) following the company's Q1 report. Ahead of the bell, Ironwood posted Q1 loss of $.38 per share with revenue of $14.6 million, versus consensus estimates looking for a loss of $.44 per share with revenue of $8.52 million.
Analyst Ram Selvaraju commented, On its earnings conference call,... More
